Week 10
The cell cycle, stem cells, and cancer
The week follows cell division from one cell to a whole tissue and then to cancer. Lecture 23 lays out the cycle: DNA synthesis in S, chromosome segregation in M, commitment at G1/S (start in yeast, the restriction point in mammals), and a G2 check that replication is done. A constant cyclin-dependent kinase is switched on by cyclins that rise and fall in a fixed order and pick its targets. The evidence comes from Hartwell's screen for temperature-sensitive cdc mutants in haploid yeast (cdc28, the yeast CDK, arrests unbudded in G1), the rad9 mutant that skips the G2 delay after X-ray damage and dies, and Xenopus egg extracts. In the extracts, M cyclin mRNA alone restores cycling after RNase, and a cyclin lacking its destruction box cannot be polyubiquitinated and degraded, so the extract arrests in mitosis. Lecture 24 uses the intestinal lining, renewed every four to five days, to show tissue homeostasis. Multipotent, self-renewing stem cells at the crypt base stay stem cells while they receive Wnt from Paneth and stromal cells. Wnt works by inhibiting the APC-containing destruction complex that would otherwise mark β-catenin for destruction. Daughters that leave the niche differentiate, ride up the villus, and are shed by apoptosis, which is held back by survival signals and triggered by kill signals such as irreparable DNA damage. Lecture 25 sorts cancer genes into proto-oncogenes (stuck accelerator), tumor suppressors (failed brakes), and caretakers such as BRCA1, then walks through the G1/S switch in which G1 cyclin-CDK phosphorylates Rb to free E2F. Retinoblastoma shows why a recessive tumor suppressor is inherited as a dominant predisposition that needs loss of heterozygosity, and APC mutation in familial adenomatous polyposis shows how blocking the crypt conveyor starts colon cancer. The lecture ends with the BCR-ABL fusion in chronic myelogenous leukemia and Gleevec, which locks that kinase inactive.
Objectives
- Explain how cyclins, appearing and disappearing in a fixed order, activate a CDK whose level stays constant and choose its substrates (S cyclin-CDK for replication proteins such as helicase, M cyclin-CDK for spindle proteins), and match cyclin and CDK curves to the phases G1, S, G2, and M
- Explain the logic of Hartwell's screen (haploid yeast, a chemical mutagen, replica plating at a permissive 22 °C and a restrictive 36 to 37 °C, uniform arrest judged by bud size), and use arrest-and-release experiments to place a cdc gene in the cycle or complementation by a human gene to test whether it is conserved
- Interpret the rad9 experiment (irradiated wild-type yeast delay in G2 and survive, rad9 mutants enter mitosis with damaged DNA and die), and predict G2/M progression in a network where p53 inhibits PIK1, PIK1 inhibits Wee1/Myt1 and activates CDC25, and these inactivate or activate Cdk1-cyclin B
- Describe how an E3 ubiquitin ligase recognizes M cyclin's destruction box and polyubiquitinates it for the proteasome, and predict the Xenopus egg extract results with RNase, with only M cyclin mRNA added back, and with a non-degradable cyclin (arrest in mitosis)
- Describe the crypt-to-villus conveyor (self-renewing, multipotent stem cells at the crypt base kept in place by Wnt from Paneth and stromal cells, daughters that differentiate once they leave the niche, shedding at the villus tip), classify cells as totipotent, pluripotent, multipotent, unipotent, or differentiated, and explain how organoid or transplant experiments show that a cell is a stem cell
- Explain the double-negative logic of Wnt signaling, in which Wnt inhibits the APC-containing destruction complex that otherwise phosphorylates β-catenin for ubiquitin-mediated destruction, and predict β-catenin and cyclin D levels when APC is lost or another pathway component is mutated
- Explain tissue homeostasis as renewal balanced by apoptosis, distinguish kill signals (irreparable DNA damage) from survival signals such as growth factors whose loss releases the brake on apoptosis, and explain why slow-dividing stem cells carry fewer mutations than transit-amplifying cells and why that protects against cancer
- Classify genes as proto-oncogenes (growth signals, Wnt, G1 cyclin, CDK, E2F, ABL), tumor suppressors (Rb, growth inhibitors, APC), or caretakers (BRCA1) from their normal function, say whether cancer needs a gain or a loss of function in each, and explain how the BCR-ABL translocation makes a constitutively active kinase that Gleevec locks inactive
- Explain how Rb holds E2F until G1 cyclin-CDK phosphorylates it, why familial retinoblastoma is bilateral and inherited as a dominant predisposition while sporadic cases are unilateral, list ways to lose heterozygosity (point mutation, chromosome loss, deletion, promoter methylation), and apply the same logic to APC and colon polyps
Reading
| Life 11.2 | How the eukaryotic cycle is controlled: cyclin-CDK complexes, checkpoints, and growth factors that push cells past G1/S. MIT assigned 11.1 to 11.5 for lecture 23, but 11.1 and 11.3 to 11.5 (cell division, mitosis, meiosis) were already read in week 5. |
| Life 11.6 | Programmed cell death and why organisms need it, for lecture 24's apoptosis. MIT also assigned 11th-edition 19.1 and 19.5 on development and stem cells, which have no counterpart in the 12th edition, so the stem cell material comes from the lecture and Recitation 16. |
| Life 11.7 | How unregulated division leads to cancer: oncogenes and tumor suppressors such as Rb. It goes with lecture 25, and MIT kept it as the reading for lecture 26 next week. |
Lectures
| 23 | Cell cycle and checkpoints | 48:19 |
| 24 | Stem cells, apoptosis, and tissue homeostasis | 46:03 |
| 25 | Cancer 1 | 51:02 |
| 2:25:24 |
Recitations
Recitation 16: Cell cycle and stem cells
Reviews lectures 23 and 24: the four phases of the cell cycle, cyclins and CDKs and their discovery in yeast by Hartwell and Nurse, conditional (temperature-sensitive) mutants found by replica plating, stem cells and their niches, and potency from totipotent to unipotent. The problems place a cdc gene with arrest-and-release experiments and work through potency, a bone marrow transplant, and a lineage tree.
- (1) A temperature-sensitive Cdc X yeast mutant grows normally at 22 °C but arrests at one phase of the cell cycle at 36 °C. Experiment 1: cells grown at 22 °C with nocodazole (an inhibitor of microtubule assembly) arrest; nocodazole is removed and the cells are shifted to 36 °C, and they divide once and arrest. Experiment 2: cells grown at 22 °C with p21cip1 (which blocks entry into mitosis) arrest; p21cip1 is removed and the cells are shifted to 36 °C, and they divide once and arrest. Experiment 3: cells grown at 36 °C until they arrest are shifted to 22 °C with hydroxyurea (an inhibitor of DNA replication), and they divide once and arrest. Where in the cycle does Cdc X most likely act: the G1-S, S-G2, G2-M, or M checkpoint? Explain.
- (2a) Classify as totipotent, pluripotent, bipotent, unipotent, or differentiated: cells that can differentiate into many cell types.
- (2b) Classify as totipotent, pluripotent, bipotent, unipotent, or differentiated: a zygote about to start cleavage.
- (2c) Classify as totipotent, pluripotent, bipotent, unipotent, or differentiated: a cardiac muscle cell.
- (3a) A patient has a rare recessive disorder, caused by loss of one gene's function, that reduces immune function. A bone marrow transplant relieves the symptoms so that the patient can lead a normal life. Why does the transplant work?
- (3b) The patient marries a man who is a carrier for the disorder. What is the probability that their child inherits the disease if they have the child before the transplant, and if they have it after?
- (4a) Four human embryonic cell lines prepared from the same embryo are tested in vitro. Line A gives motor neurons; line B gives motor, sensory, lateral, and hippocampal neurons; line C gives sensory, lateral, and hippocampal neurons; line D gives motor and sensory neurons. Rank their potency from 1 (most potent) to 4 (least potent).
- (4b) Draw a lineage tree for cell lines A to D from the same data.
Homework
Problem Set 5: SNP mapping, signaling, neurons, cell cycle, and stem cells
Due with lecture 25 (November 9, 2018).
- (1a) A pedigree of PKU, caused by a mutation in the PAH gene: unaffected parents 1 (male) and 2 (female) have an unaffected son 4, an unaffected daughter 5, an affected son 6, and an unaffected son 7. Son 4 and his unaffected wife 3 have an unaffected son 8, an affected daughter 9, and an unaffected son 10. Two SNPs tightly linked to PAH are typed: individual 1 is SNP1 A/G and SNP2 T/C, with A and T on one chromosome and G and C on the other; individual 2 is SNP1 T/G, SNP2 A/C; individual 3 is SNP1 A/G, SNP2 T/C; individual 6 is SNP1 G/G, SNP2 C/C; individual 7 is SNP1 A/T, SNP2 T/A. Assume complete penetrance and no new mutations. What is the mode of inheritance of this form of PKU?
- (1b) In the PKU pedigree, what is the probability that individual 5 is a carrier?
- (1c) If individual 5 is a carrier, what are her possible SNP genotypes? Assume no recombination.
- (1d) From the SNP profile, give all possible PAH genotypes of individual 7, writing A or XA for the allele that gives the dominant phenotype and a or Xa for the recessive one.
- (2a) Adrenaline signaling: step 1, adrenaline arriving through the blood binds the β-adrenergic GPCR, whose conformational change makes the attached G protein release GDP and bind GTP; step 2, the GTP-bound G protein detaches and activates adenylate cyclase, and it is switched off when it hydrolyzes GTP to GDP; step 3, adenylate cyclase makes cAMP from ATP; step 4, cAMP diffuses through the cell and activates protein kinase A (PKA), which phosphorylates many proteins, raising heart rate in the fight-or-flight response. Cells are treated with cholera toxin, which locks activated G proteins with GTP bound (#1); with pertussis toxin, which locks G proteins with GDP bound (#2); or have a receptor that activates G proteins without ligand (#3). In which condition is adenylate cyclase constitutively active independent of adrenaline? Explain.
- (2b) Why is the effect of adrenaline limited to specific cell types in an individual?
- (2c) Is adrenaline signaling endocrine, apocrine, autocrine, or juxtacrine? Explain why you chose this option over the others.
- (2d) At which step (1, 2, 3, or 4) does the adrenaline signal first get amplified?
- (2e) Consider homozygous mutations: M1, the β-adrenergic receptor stays in its ligand-bound form; M2, adenylate cyclase can no longer bind ATP; M3, PKA stays active; M4, the receptor lacks 4 of its 7 transmembrane domains. For cells with M1 and M3, with M2 and M4, and with M2 and M3, incubated with adrenaline, give the cAMP concentration (high or low), whether PKA is active, and whether heart rate increases or decreases compared with wild-type cells given adrenaline.
- (2f) Unlike adrenaline, testosterone (a four-ring steroid with one hydroxyl and one ketone) diffuses into its target cells and binds an intracellular receptor. What property lets it diffuse in?
- (3a) A diagram shows the β-adrenergic receptor, with seven transmembrane helices, its N terminus outside the cell, and its C terminus in the cytoplasm, and a small G protein on the cytoplasmic face anchored by a covalently attached lipid. Choosing from cytoplasm, nucleus, rough ER, smooth ER, vesicles, and cell membrane, where does translation of the β-adrenergic receptor begin, and where does translation of the G protein begin?
- (3b) Using the same options, where is translation of the β-adrenergic receptor completed, and where is translation of the G protein completed?
- (3c) Where is the newly made G protein covalently coupled to its lipid?
- (3d) Which intracellular structure carries both newly made proteins to the cell membrane?
- (3e) Which of the two proteins has a signal sequence, and what does it do?
- (3f) On the receptor diagram, circle the part of the β-adrenergic receptor that secreted proteins do not have.
- (3g) On a drawing of the ER membrane (cytoplasm above, ER lumen below), can you label the NH2 and COOH ends of (i) the β-adrenergic receptor as it is being translated, and (ii) the G protein? If yes, draw it; if no, write No.
- (4a) A neuron in a dish is treated with a reversible ATP synthase inhibitor. Would this inhibit a pump or a channel? Explain.
- (4b) In multiple sclerosis the immune system destroys the myelin sheath. Does action potential propagation slow down, speed up, or stay the same? Explain.
- (4c) GABA acts on GABA-A receptors, which are ligand-gated Cl⁻ channels, and GABA-B receptors, which open K⁺ channels through G proteins. When GABA-A is activated, do Cl⁻ ions flow into or out of the target neuron, and how does this change the chance of an action potential? Explain.
- (4d) A GABA-producing neuron is given an excitatory stimulus after treatment with tetraethylammonium (TEA), which blocks voltage-gated K⁺ channels (plate A), or tetrodotoxin (TTX), which blocks voltage-gated Na⁺ channels (plate B). On axes of membrane potential against time, with resting potential −70 mV and threshold −55 mV, sketch the action potential in each plate, or write that there is none.
- (5a) C. elegans flattens its body in response to ethanol. Loss-of-function slo mutants are resistant and do not flatten; null npr mutants flatten even without ethanol. On a diagram where ethanol drives the change from normal movement to body flattening, mark whether wild-type slo and wild-type npr activate (arrow) or inhibit (T-bar) the response.
- (5b) slo is expressed in the PVM neurons, and a PVM-specific promoter is used to express channelrhodopsin there. What stimulus opens channelrhodopsin?
- (5c) Starting from a slo loss-of-function mutant, explain how you would use channelrhodopsin to test whether activating the PVM neurons can make up for slo in the ethanol response, and what result you would expect.
- (6a) Cdk1-cyclin B drives the G2/M transition and is active when dephosphorylated. DNA damage or unfinished replication activates p53; p53 inhibits PIK1; PIK1 inhibits the Myt1/Wee1 kinase and activates CDC25; Myt1/Wee1 inactivates Cdk1 and CDC25 activates it. Given that proto-oncogene mutations are dominant gain of function and tumor suppressor mutations recessive loss of function, which of Myt1, PIK1, p53, CDC25, Cdk1, and cyclin B are encoded by (i) proto-oncogenes and (ii) tumor suppressor genes?
- (6b) In a diploid yeast, cyclin B (M cyclin) acts at the G2/M transition. A temperature-sensitive cyclin B mutant fails to complete the cell cycle at 42 °C because it arrests at a particular phase. Is the arrested cell n, 2n, or 4n?
- (6c) Would a temperature-sensitive PIK1 mutant at 42 °C progress from G2 to M? Why or why not?
- (6d) Cisplatin disrupts DNA replication and so activates the DNA damage checkpoint through p53. How would this checkpoint slow tumor growth?
- (6e) From the structures of phenylalanine, alanine, tryptophan, and serine, circle the amino acid that cyclin D-CDK can phosphorylate.
- (7a) A drawing of the mouse cardiac stem cell (CSC) lineage shows self-renewing CSCs giving self-renewing primordial cardiac progenitors, then early cardiomyocytes, then mature cardiomyocytes. List two characteristics that make CSCs stem cells.
- (7b) Briefly describe one experiment to test whether a test cell is likely to be a CSC.
- (7c) CSCs express the transcription factors Oct4 and Nanog and the cell surface protein CD90. Which would you use to purify living CSCs from a mixed population? Explain.
- (7d) In adults, CSCs live in niches and need EGF and FGF to divide and differentiate. CSCs are removed from mutant mouse embryos 1 and 2, and GFP-labeled CSCs from a normal embryo are implanted into both. The GFP cells divide and form the CSC lineage in embryo 1 but not in embryo 2. Why?
Check your work against the solutions.